Core Insights - Scinai Immunotherapeutics Ltd. has announced successful preclinical study results for its anti IL-17A/F VHH antibody fragment ('NanoAb'), which is designed as a local treatment for mild to moderate plaque psoriasis, addressing a significant unmet medical need in this patient population [1][13][20] Market Need - Approximately 13 million patients are diagnosed with plaque psoriasis in major markets, with 50% suffering from mild disease and 28% from moderate psoriasis [2] - Current treatments for mild to moderate plaque psoriasis are primarily corticosteroids and phototherapy, which have limitations such as frequent use, local adverse effects, and low patient adherence [2][10] - The existing therapies for moderate to severe psoriasis are biologics and JAK inhibitors, which are expensive and carry long-term health risks [2] Study Overview - The study included Scinai's anti-IL-17 NanoAbs, two comparator drugs (Betamethasone and Secukinumab), and a negative control [4] - The anti-inflammatory effects were evaluated by measuring cytokine levels and conducting histopathological analysis [4][11] - Results indicated that the intralesional injection of the NanoAb could reduce psoriatic lesion severity and improve skin integrity [5][18] Product Development - Scinai's product candidate aims to provide a local, intradermal treatment that minimizes side effects associated with systemic biologics and corticosteroids [10] - The treatment is designed to be administered using a short, painless needle, allowing for low-frequency applications [10] - The company plans to conduct further studies to fine-tune dosing and drug half-life, with a follow-up in-vivo animal study scheduled for late 2024 [20]
Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model